September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Sustained Delivery of Ranibizumab: The LADDER Trial of the Ranibizumab Port Delivery System
Author Affiliations & Notes
  • J Jill Hopkins
    Ophthalmology, Genentech, South San Francisco, California, United States
  • Carl D Regillo
    Wills Eye Hospital, Philadelphia, Pennsylvania, United States
    Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  • Aaron Osborne
    Ophthalmology, Genentech, South San Francisco, California, United States
  • Steven F Francom
    Ophthalmology, Genentech, South San Francisco, California, United States
  • Giulio Barteselli
    Ophthalmology, Genentech, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   J Hopkins, Genentech, Inc (E); Carl Regillo, Genentech, Inc (C), Genentech, Inc (F); Aaron Osborne, Genentech, Inc (E); Steven Francom, Genentech, Inc (E); Giulio Barteselli, Genentech, Inc (E)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 530. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J Jill Hopkins, Carl D Regillo, Aaron Osborne, Steven F Francom, Giulio Barteselli; Sustained Delivery of Ranibizumab: The LADDER Trial of the Ranibizumab Port Delivery System. Invest. Ophthalmol. Vis. Sci. 2016;57(12):530.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The use of anti-VEGF intravitreal (ITV) injections to treat retinal diseases including neovascular age-related macular degeneration (nAMD) is well-established. However, treatment often requires frequent ITV injections, which can be burdensome. The phase 2 LADDER trial is evaluating the Ranibizumab (RBZ) Port Delivery System (RPDS), a refillable implanted device, in patients with nAMD. The RPDS uses a diffusion-controlled drug delivery mechanism to provide sustained ITV release of RBZ between refills. LADDER follows a phase 1 open-label study of the RPDS in 20 treatment-naïve patients with nAMD, which established proof-of-concept for RPDS safety and efficacy.

Methods : LADDER is a phase 2 multicenter, randomized, interventional, active-treatment controlled clinical trial, with the primary endpoint 9 months after last patient randomization. Eligible patients have subfoveal nAMD, diagnosed within 6 months, with documented response to ITV anti-VEGF treatment. Patients are randomized 3:3:3:2 to RPDS with 1 of 3 RBZ formulations (N=60 each) or monthly ITV RBZ 0.5 mg (N=40). The RPDS is surgically implanted in the pars plana (subconjunctival), and refills are performed in the clinic using a customized refill needle that exchanges the reservoir contents with fresh drug.

Results : LADDER anticipates enrolling 220 patients at up to 55 US sites. The primary objective is to evaluate the time to the first RPDS refill according to protocol-defined refill criteria. The key secondary endpoint, change from baseline in BCVA, will be used to test the non-inferiority (NI) of each of the RPDS arms vs monthly ITV RBZ 0.5 mg using a 4 letter NI margin. Other secondary outcomes include: mean change in BCVA from baseline (BL) to Month 9, mean average change in BCVA through Month 9, mean change from BL in central foveal thickness on SD-OCT, and adverse event (AE) incidence (ocular, non-ocular, AEs of special interest).

Conclusions : Sustained delivery has the potential to reduce the treatment burden associated with anti-VEGF injections for patients and improve visual outcomes associated with under-treatment in clinical practice. LADDER is an ongoing phase 2 study evaluating dosing and functional outcomes with sustained delivery of RBZ via the RPDS.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×